The value of microRNA-21 as a biomarker for the prognosis of lung cancer
A protocol for systematic review and meta-analysis

Wei Zhang, MDa, Lin Wei, MDa, Rong Luo, MD, Hui Liu, MDa, Jing Chen, MDa,∗

Abstract

Background: More and more studies are investigating the influence of the expression of MicroRNA-21 (miRNA-21) on prognosis and clinical significance in patients with lung cancer, but the results are contradictory and uncertain. A meta-analysis was conducted with controversial data to accurately assess the issue.

Methods: A detailed search of relevant research in Wanfang, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI), the Chongqing VIP Chinese Science and Technology Periodical Database, PubMed, Embase, Web of Science and other databases. Two reviewers independently conducted data extraction and literature quality evaluation. Odds ratio and its 95% confidence intervals were used to evaluate the relationship between miRNA-21 and clinicopathological characteristics of lung cancer patients. Hazard ratios and its 95% confidence intervals To assess the prognostic effect of miRNA-21 on overall survival and disease-free survival. Meta analysis was performed using RevMan 5.3 and Stata 14.0 software.

Results: This study will provide a high-quality evidence-based medical evidence of the correlations between miRNA-21 expression and overall survival, disease-free survival and clinicopathological features.

Conclusion: The study will provide updated evidence to evaluate whether the expression of miRNA-21 is in association with poor prognosis in patients with lung cancer.

Ethics and dissemination: The private information from individuals will not publish. This systematic review also will not involve endangering participant rights. Ethical approval is not available. The results may be published in a peer-reviewed journal or disseminated in relevant conferences.

OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/X3MD6

Abbreviations: CIs = confidence intervals, DFS = disease-free survival, HRs = hazard ratios, miRNA = microRNA, OS = overall survival, PRISMA-P = Preferred Reporting Items for Systematic Reviews and MetaAnalysis Protocols.

Keywords: lung cancer, meta-analysis, miRNA-21, prognosis

1. Introduction

It is estimated that there will be 1735350 new cases of cancer patients and 609640 deaths, according to the 2018 National Cancer Center statistics.[1] This shows that cancer is still the main public health problem and challenge we face. Lung cancer is 1 of the malignant tumors with high morbidity and mortality worldwide and its prognosis is poor, the 5-year survival rate is <15%.[2] According to the CONCORD-3 project of the American Cancer Society and the Centers for Disease Control and Prevention, the global lung cancer incidence accounts for about 13% of all cancer incidences, of which 12.5% in developed
regions and 13.3% in underdeveloped regions.\textsuperscript{[5]} In 2018, the number of new lung cancer deaths and deaths in the world was 2.094 million and 1.76 million respectively, and the number of new lung cancer deaths and deaths in the Chinese population was 774,000 and 691,000, respectively. The overall morbidity and mortality are increasing year by year.\textsuperscript{[3]}

The onset of lung cancer is often hidden. Most patients are diagnosed in the middle and late stages and have lost the opportunity for radical treatment, so the main treatment measures at this stage are chemotherapy or targeted therapy. But Many patients have poor prognosis due to the presence of cancer cell metastasis and insensitivity to radiotherapy and chemotherapy, and the mortality rate is as high as 85%.\textsuperscript{[4]} Tumor marker refers to a type of substance that exists or is secreted in tumor cells and can reflect tumor occurrence and development, and monitor tumor response to treatment, including tumor antigens, hormones, glycoproteins, enzymes and isoenzymes, oncogenes, and tumor suppressor gene.\textsuperscript{[5]} Therefore, it is of great significance to actively search for and study factors related to the prognosis of lung cancer.

MicroRNA (miRNA) is a type of small RNA with a length of 18–25 amino acids and no protein coding function.\textsuperscript{[6]} miRNA can bind with the 3'UTR sequence of mRNA to degrade mRNA or inhibit the transcription of mRNA, thereby participating in the biological processes of regulating cell proliferation, differentiation, apoptosis and innate immunity.\textsuperscript{[7]} Gallach and so on have reported that miRNA may be involved as an oncogene or tumor suppressor gene in the occurrence and development of various tumors including lung cancer.\textsuperscript{[8]}

Multiple studies have shown that the high expression of miRNA-21 is closely related to the survival of lung cancer patients, but there are also large differences in the research results. Some studies have shown that the expression of miRNA-21 is positively correlated with the survival rate of lung cancer patients,\textsuperscript{[9–13]} but some studies have shown that the expression of miRNA-21 is negatively correlated with the survival rate of lung cancer patients.\textsuperscript{[14,15]} In order to more accurately analyze the effect of high expression of miRNA-21 on the survival of lung cancer patients.\textsuperscript{[14]} This study comprehensively searched the literature related to the expression of miRNA-21 and the prognosis of lung cancer patients, and used meta-analysis to evaluate the effect of high expression of miRNA-21 on the prognosis of lung cancer patients.

2. Methods

2.1. Study registration

This meta-analysis protocol is based on the Preferred Reporting Items for Systematic Reviews and meta-analysis Protocols (PRISMA-P) statement guidelines.\textsuperscript{[1]} The PRISMA-P checklist for the protocol is provided in the PRISMAP-checklist.

The protocol of the systematic review has been registered on Open Science Framework. The registration number is DOI 10.17605/OSF.IO/X3MD6

2.2. Data sources and search strategy

Wanfang, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database, PubMed, Embase, Web of Science and other databases will be our electronic databases for retrieval. The retrieval time is from their inception to May 2020. The retrieval strategy will be created based on discussion of all the researchers on the basis of the Cochrane handbook guidelines. The following search terms will be used: “lung cancer”, “lung neoplasm”, “miRNA-21”, “microRNA-21”, “miR-21”, “prognostic”, and “survival”. The search strategy for PubMed is shown in Table 1. The retrieval strategy can be modified according to the actual situation of other electronic databases.

| Number | Search terms |
|--------|--------------|
| 1      | miRNA-21 [Title/Abstract] |
| 2      | “microRNA-21” [Title/Abstract] |
| 3      | miR-21[Title/Abstract] |
| 4      | hsa-miR-21[Title/Abstract] |
| 5      | 1 OR 2 OR 3 OR 4 |
| 6      | Lung Neoplasms [MeSH] |
| 7      | Carcinoma, Non-Small-Cell Lung [MeSH] |
| 8      | Carcinoma, Small Cell [MeSH] |
| 9      | Cancer of Lung [Title/Abstract] |
| 10     | Lung Cancer [Title/Abstract] |
| 11     | Pulmonary Cancer [Title/Abstract] |
| 12     | Pulmonary Neoplasms [Title/Abstract] |
| 13     | Cancer of the Lung [Title/Abstract] |
| 14     | Neoplasms, Lung [Title/Abstract] |
| 15     | Neoplasms, Pulmonary [Title/Abstract] |
| 16     | Cancer, Lung [Title/Abstract] |
| 17     | Cancer, Pulmonary [Title/Abstract] |
| 18     | Cancers, Lung [Title/Abstract] |
| 19     | Cancers, Pulmonary [Title/Abstract] |
| 20     | Lung Cancers [Title/Abstract] |
| 21     | Lung Neoplasm [Title/Abstract] |
| 22     | Neoplasm, Lung [Title/Abstract] |
| 23     | Neoplasm, Pulmonary [Title/Abstract] |
| 24     | Pulmonary Cancers [Title/Abstract] |
| 25     | Pulmonary Neoplasm [Title/Abstract] |
| 26     | Carcinoma, Non-Small-Cell Lung [Title/Abstract] |
| 27     | Non-Small Cell Lung Cancer [Title/Abstract] |
| 28     | Non-Small-Cell Lung Carcinoma [Title/Abstract] |
| 29     | Non-Small-Cell Lung Carcinoma [Title/Abstract] |
| 30     | Carcinoma, Small Cell Lung [Title/Abstract] |
| 31     | Carcinomas, Non-Small-Cell Lung [Title/Abstract] |
| 32     | Lung Carcinoma, Non-Small-Cell [Title/Abstract] |
| 33     | Lung Carcinomas, Non-Small-Cell [Title/Abstract] |
| 34     | Non Small Cell Lung Carcinoma [Title/Abstract] |
| 35     | Non-Small-Cell Lung Carcinomas [Title/Abstract] |
| 36     | Oat Cell Carcinomas of Lung [Title/Abstract] |
| 37     | Carcinoma, Small Cell Lung [Title/Abstract] |
| 38     | Oat Cell Lung Cancer [Title/Abstract] |
| 39     | Small Cell Cancer Of The Lung [Title/Abstract] |
| 40     | Small Cell Lung Cancer [Title/Abstract] |
| 41     | Small Cell Lung Carcinoma [Title/Abstract] |
| 42     | 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 |
| 43     | survival[Title/Abstract] |
| 44     | prognosis*[Title/Abstract] |
| 45     | 43 OR 44 |
| 46     | 5 AND 42 AND 45 |

miRNA = microRNA, MeSH = medical subject heading.
2.3. Inclusion criteria for study selection

The included articles must meet the following inclusion criteria:

1. Patients diagnosed with lung cancer based on pathology and histology.
2. miRNA-21 expression in tumor tissues.
3. Reported miRNA-21 survival-related data, including overall survival (OS) and disease-free survival (DFS).
4. Patients are divided into miRNA-21 positive (high) and miRNA-21 negative (low).
5. The article provides the relationship between miRNA-21 expression and clinical pathological characteristics.
6. Published as full-text articles, original Chinese and English Research papers.

If there are repeated articles, choose articles with higher quality and larger sample size. Conference abstract, case series report, letters, animal experiments, lack of measurement indicators and survival Research are not included.

2.4. Data collection and analysis

2.4.1. Selection of studies. In order to ensure the correctness of the included studies, all researchers have received evidence-based training, and adhered to the process summarized in the light of the PRISMA flow diagram (Fig. 1). All results retrieved from the electronic database are imported into endnote 8.0. First, delete duplicate documents through endnote 8.0. Then, the 2 researchers independently screened based on the title, abstract and keywords of the literature to remove irrelevant literature. The remaining literature will be further confirmed by the 2 researchers by reading the full text. Excluded studies and reasons for exclusion will be recorded. The differences between the 2 researchers will be resolved by consensus or by a third independent arbitrator.

Figure 1. Flow diagram of study selection process.
2.4.2. Data extraction and management. Data were double input to EpiData software (version 3.0; The EpiData Association, Odense, Denmark) by 2 investigators. Differences were resolved through group discussions. The information extracted includes the name of the first author and the year of publication, country, histology type, tumor stage, sample size, miRNA-21 detection method, and hazard ratios (HRs) and 95% confidence intervals (CIs) for OS, and DFS, if provided. We obtained HRs and 95% CIs from the Kaplan-Meier survival curves through using Engauge Digitizer version 4.1 (http://digitizer.sourceforge.net).

2.5. Assessment of quality in included studies

Newcastle Ottawa Scale was used to evaluate the quality of the literature, including a total of 3 items and 8 items. The 2 researchers scored the literature according to the scored items, and the differences were resolved by group discussions. Selectivity from the study population The measurement of comparability, exposure between groups, and exposure factors were developed, with a perfect score of 9 points, and documents with a score of ≥7 were judged to be of higher quality.

2.6. Measures of prognosis

OS and DFS will be taken as prognostic outcomes. The results will be expressed as HRs with 95% CIs.

2.7. Management of missing data

If there is insufficient or missing data in the literature, we will contact the author via email to request the data. If the data is not available, we will only analyze the currently available data and discuss its potential impact.

2.8. Statistical analysis

Statistical analysis was performed using STATA 14.0 (STATA Corporation, College Station, TX) and RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The 95% CIs and HRs was used to evaluate the relationship between miRNA-21 expression and OS and DFS. Odds ratio and 95% CIs were used to evaluate the impact of miRNA-21 expression on clinicopathological characteristics. First, statistical heterogeneity tests were performed on the included studies. If there is no statistical heterogeneity among the included literatures ($I^2 \leq 50\%$, $P \geq 1$), a fixed effect model is used; when there is statistical heterogeneity among the included literatures ($P < .1$, $I^2 > 50\%$), the sources of heterogeneity will be analyzed. Clinical heterogeneity will be treated by subgroup analysis. In the absence of significant clinical heterogeneity and methodological heterogeneity, statistical heterogeneity will be considered, and random effects models will be used for analysis. If the clinical heterogeneity of the subgroup analysis is significantly higher, no meta-analysis will be performed, only a descriptive analysis.

2.9. Additional analysis

2.9.1. Subgroup analysis. We will conduct a subgroup analysis based on the type of lung cancer, the detection method of miRNA-21 expression, the patient’s age, race, and source of survival data.

2.9.2. Sensitivity analysis. The sensitivity analysis of each index was carried out by 1-by-1 elimination method to check the stability of the results.

2.9.3. Reporting bias. If the number of studies included in a certain outcome index is no less than 10, funnel chart is used to evaluate publication bias. Besides, Egger and Begg test were used for the evaluation of potential publication bias.

3. Discussion

Data from 36 cancer incidences and deaths in 185 countries around the world show that there were approximately 2,093 million (11.6%) new cases of lung cancer in the world, and approximately 17.61 million (18.4%) deaths, ranking first in all malignant tumors in 2018.[1] Lung cancer mortality rate is increasing year by year in China.[17] Some studies have shown that the 5-year survival rate of early lung cancer can reach more than 90% after treatment, however, the 5-year survival rate after treatment of advanced lung cancer is less than 5%.[18,19] Therefore, finding biomarkers with high specificity and high sensitivity has important clinical significance for the early diagnosis and prognosis of lung cancer.

In recent years, a large number of studies have shown that miRNA-21 plays an important role in the occurrence and development of lung cancer. Capodanno et al.[12] found that miRNA-21 is increased in lung cancer tissues, and miRNA-21 can be used as a biomarker to distinguish lung cancer tissues from normal tissues. Zhang et al.[20] found that the levels of miRNA-21 in the plasma of lung cancer patients were significantly higher than those of healthy people. In addition, the plasma miR-21 levels of lung cancer patients were significantly reduced after surgery. High expression of miRNA-21 is a risk factor for the prognosis of lung cancer.[21] Liu et al.[22] found that the expression level of miRNA-21 in lung adenocarcinoma cells, squamous cell carcinoma cells and lung cancer tissues was significantly higher than that of human bronchial epithelial cells and adjacent tissues. miRNA-21 as an oncogene participates in regulating the occurrence and development of lung cancer by regulating the PTEN signaling pathway. Ma et al.[23] found that down-regulation of miRNA-21 can inhibit the proliferation of cells by inhibiting the PI3K/Akt signaling pathway, promote cell apoptosis, and enhance the sensitivity of radiation-resistant cells A549 to ionizing radiation. Yang et al.[24] found that miRNA-21 can be used as a biomarker for lung cancer. The AUC value of the ROC curve for the diagnosis of NSCLC is 0.81, and the sensitivity and specificity are 69% and 71%, respectively. Increased expression of miRNA-21 may be involved in the occurrence and development of lung cancer, resulting in decreased OS. To this end, we hope that this meta-analysis will provide more accurate and objective evidence for the relationship between miRNA-21 expression and prognosis in lung cancer patients.

Our research has certain limitations. First, the detection method and threshold of miRNA-21 expression may be different. In addition, there are various treatment methods for patients, such as surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Therefore, there may be a risk of heterogeneity. In addition, this study only includes studies published in English and Chinese, so important studies or reports published in other languages may be omitted.
Author contributions
Conceptualization: Wei Zhang and Jing Chen.
Data collection: Wei Zhang and Lin Wei.
Funding acquisition: Jing Chen.
Resources: Lin Wei and Rong Luo.
Software: Liu Hui.
Supervision: Lin Wei and Rong Luo.
Writing – original draft: Wei Zhang and Jing Chen.
Writing – review and editing: Wei Zhang and Jing Chen.

References
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians 2018;68:7–30.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. Ca A Cancer Journal for Clinicians 2017;67:7–30.
[3] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–75.
[4] Zheng YW, Li RM, Zhang XW, et al. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 2013;31:197–205.
[5] Chen Z-q, Huang L-s, Zhu B. Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer. Dis Markers 2018;2018:9845123.
[6] Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015;518:107–10.
[7] Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nature reviews. Genetics 2015;16:421–33.
[8] Gallach S, Jantus-Lewintre E, Calabuig-Fariñas S, et al. MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value. Onco Targets and Therapy 2017;10:56143–57.
[9] Markou A, Tsaroucha EG, Kaklamanis I, et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008;54:1696–704.
[10] Gao W, Shen H, Liu L, et al. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011;137:557–66.
[11] Wang ZX, Bian HB, Wang JR, et al. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol 2011;104:847–51.
[12] Capodanno A, Boldrini L, Proietti A, et al. Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol 2013;43:763–74.
[13] Zhao W, Zhao JI, Zhang L, et al. Serum miR-21 level: a potential diagnostic and prognostic biomarker for non-small cell lung cancer. International journal of clinical and experimental medicine 2015;8:14759–63.
[14] Liu XG, Zhu WY, Huang YY, et al. High expression of serum miR-21 and tumor miR-205c associated with poor prognosis in patients with lung cancer. Medical oncology (Northwood, London, England) 2012;29:618–26.
[15] Voortman J, Goto A, Mendiboure J, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010;70:8288–98.
[16] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Sys Rev 2015;4:1–9.
[17] Wang L, Yu C, Liu Y, et al. Lung cancer mortality trends in China from 1988 to 2013: new challenges and opportunities for the government. International journal of environmental research and public health 2016;13.
[18] Angiogenesis biomarkers may be useful in the management of patients with indeterminate pulmonary nodules. Ann Thorac Surg 2015;100:429–36.
[19] Vazquez M, Carter D, Brambilla E, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer 2009;64:148–54.
[20] Zhang H, Mao F, Shen T, et al. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett 2016;13:669–76.
[21] Yang M, Shen H, Qu C, et al. High expression of miR-21 and miR-153 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 2013;49:604–15.
[22] Liu ZL, Wang H, Liu J, et al. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 2013;372:35–45.
[23] Ma Y, Xia H, Liu Y, et al. Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt. Biomed Res Int 2014;2014:617868.
[24] Yang JI, Li BJ, Liu HW, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol 2015;36:3035–42.